In a prespecified secondary analysis of 83 patients enrolled in mainland China with pretreated HR+/HER2− metastatic breast cancer, datopotamab deruxtecan vs chemotherapy numerically improved median PFS (8.1 vs 4.2 months; HR 0.54); OS HR 0.83, not significant.
Secondary analysisn = 83
Wang et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort